SACITUZUMAB GOVITECAN for Transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 78 adverse event reports in the FDA FAERS database where SACITUZUMAB GOVITECAN was used for Transitional cell carcinoma.
Most Reported Side Effects for SACITUZUMAB GOVITECAN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Disease progression | 389 | 30.9% | 62 | 55 |
| Diarrhoea | 184 | 14.6% | 37 | 111 |
| Death | 182 | 14.4% | 182 | 21 |
| Inappropriate schedule of product administration | 147 | 11.7% | 19 | 43 |
| Neutropenia | 128 | 10.2% | 20 | 60 |
| Off label use | 111 | 8.8% | 25 | 38 |
| Fatigue | 109 | 8.6% | 15 | 40 |
| Febrile neutropenia | 92 | 7.3% | 20 | 88 |
| Asthenia | 90 | 7.1% | 33 | 48 |
| Weight decreased | 89 | 7.1% | 9 | 32 |
| Nausea | 87 | 6.9% | 10 | 36 |
| Weight fluctuation | 81 | 6.4% | 11 | 28 |
| Weight increased | 66 | 5.2% | 9 | 28 |
| Constipation | 64 | 5.1% | 14 | 29 |
| Vomiting | 59 | 4.7% | 15 | 42 |
Other Indications for SACITUZUMAB GOVITECAN
Triple negative breast cancer (650)
Product used for unknown indication (127)
Breast cancer metastatic (96)
Breast cancer (59)
Transitional cell cancer of the renal pelvis and ureter (26)
Non-small cell lung cancer (24)
Transitional cell carcinoma metastatic (24)
Neoplasm (19)
Her2 positive breast cancer (18)
Breast cancer female (13)
Other Drugs Used for Transitional cell carcinoma
PEMBROLIZUMAB (1,951)
ENFORTUMAB VEDOTIN-EJFV (1,179)
GEMCITABINE (825)
ATEZOLIZUMAB (788)
CISPLATIN (672)
ENFORTUMAB VEDOTIN (649)
NIVOLUMAB (595)
AVELUMAB (554)
CARBOPLATIN (493)
GEMCITABINE\GEMCITABINE (255)